marcus

[Kate Hoey @CatharineHoey]

This is just so shocking I don’t recall the BBC allowing anyone on their programme a few days after the terrible murder of Jo Cox to criticise her political or religious views

[Belinda de Lucy @BelindadeLucy]

Dominic Cummings -

‘Whitehall will break the law to prevent Reform winning power. They’ll leak medical records, they’ll leak tax records. They’ll bug (Nigel’s) phone and leak that. They’ll do anything that they need to’.
https://t.co/a5DtIYwCIt

[marcus @mwl471]

Scancell
Regardless of this short term issue of Nasdaq and funding;

Trinity valuation for Scancell is £399m, equivalent to 39p/share.
(15p atm, current mkt cap £156m )

https://t.co/RzrJ5EdFbY

[marcus @mwl471]

Melanoma
The latest progression-free survival (PFS) is 77% at 20 months
https://t.co/v27RhYpUrh

[marcus @mwl471]

https://t.co/v27RhYpUrh
current sp 21p. Trinity says if a 50% probability of success was applied to iSCIB1+;mkt cap£645m ($806m), equivalent to 62p per share. Scancell , melanoma, Kidney, Head & Neck cancer in stage 2 and shortly stage 3 trials.

[Cormac Lucey @CormacLucey]

That brutal Belfast stabbing makes it to the top of the web editions of @thetimes and @Telegraph but neither @IrishTimes nor @Independent_ie lead with it. We live in a land of carefully curated news where political values matter more than news values. @RuadhanIT @cormacbourke

[Kate Hoey @CatharineHoey]

Excellent interview by @JimAllister

[marcus @mwl471]

@bradloncar When are they buying Scancell ? 😀

[marcus @mwl471]

@bradloncar @BiotechTV Scancell, at 20 months ,77% PFS in advanced Melanoma v 43% SOC. a massive 34 percentage point survival advantage over Ipi Nivo SOC

[marcus @mwl471]

https://t.co/ABIGBubrhy

Scancell`s CEO Phil L`huillier

Cancer immunotherapies , melanoma, head & neck, kidney, lung, ovarian, breast . 77% pfs in advanced melanoma past 20 months

[marcus @mwl471]

@biospace Scancell,20-month progression-free survival (PFS) rate of 77% in advanced melanoma v 43% associated with standard nivolumab (Opdivo) and ipilimumab (Yervoy) alone SOC (standard of care)
https://t.co/6hLtb1m2rt

[FierceBiotech @FierceBiotech]

Analysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial https://t.co/VWG8rZIjdP

[marcus @mwl471]

@FierceBiotech Scancell,20-month progression-free survival (PFS) rate of 77% in advanced melanoma v 43% associated with standard nivolumab (Opdivo) and ipilimumab (Yervoy) alone SOC (standard of care)
https://t.co/6hLtb1m2rt

[marcus @mwl471]

https://t.co/WG2p0BjmsA
Benjamin McLeod on Linkedin

"STRONGEST CANCER VACCINE SIGNAL IN 10 YEARS

Scancell showed up with numbers that made the naysayers eat their words:

[marcus @mwl471]

https://t.co/cz3pFqWSRg
you’re looking at the strongest cancer vaccine readout in a decade. Scancell

[John Griffiths @JMPlasybryn]

@Share_Talk @ZaksTradersCafe Yes Scancell had some great melanoma cancer result news this week and that has attracted quite a lot of interest (media & investors) with perhaps more to come. Was a bullish article in Biotech Voyager. A great small British Co. with world cancer relief potential. Exciting

[marcus @mwl471]

Phil L'Huillier CEO
Incredibly proud of the entire Scancell team on this milestone. FDA Fast Track designation for iSCIB1+,real unmet need in advanced melanoma.
77% progression free survival at 20 months vs. 43% for standard of care. Phase 3 planning is advancing at pace.
Linkedi

[marcus @mwl471]

https://t.co/06mbG5HcEw
you’re looking at the strongest cancer vaccine readout in a decade.

[marcus @mwl471]

FDA fast-track status adds regulatory momentum to compelling trial data. Scancell's advanced melanoma data keeps widening the gap over standard care as phase III funding race heats up.progression-free survival (PFS)77% at 20 months